Eculizumab in Typical Hemolytic Uremic Syndrome (HUS) with Neurological Involvement

Medicine (United States)

Volumn 94, Issue 24, 2015, Pages

  Pape, Lars ^a   Hartmann, Hans ^a   Bange, Franz Christoph ^a   Suerbaum, Sebastian ^a   Bueltmann, Eva ^a   Ahlenstiel Grunow, Thurid ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CATECHOLAMINE; CEFOTAXIME; COMPLEMENT COMPONENT C5 INHIBITOR; CONJUGATE VACCINE; ECULIZUMAB; SHIGA TOXIN; MONOCLONAL ANTIBODY;

ADOLESCENT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; ARTIFICIAL VENTILATION; BASAL GANGLION; CENTRAL NERVOUS SYSTEM; CHILD; COGNITIVE DEFECT; COMA; CONSCIOUSNESS; DIALYSIS; DIFFUSION WEIGHTED IMAGING; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; EXTRACORPOREAL OXYGENATION; FEMALE; GENE MUTATION; HEART FAILURE; HEMIPARESIS; HEMODIALYSIS; HEMOLYTIC UREMIC SYNDROME; HEMORRHAGIC COLITIS; HOSPITALIZATION; HUMAN; ILEOSTOMY; KOLMOGOROV SMIRNOV TEST; MALE; NEISSERIA MENINGITIDIS; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; NEUROLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS NECROSIS; PERITONEAL DIALYSIS; POLYMERASE CHAIN REACTION; PROPHYLAXIS; PROSPECTIVE STUDY; RESUSCITATION; RETROSPECTIVE STUDY; SEDATION; SEIZURE; UREMIA; WHITE MATTER; CENTRAL NERVOUS SYSTEM DISEASES; COMPLICATION; ESCHERICHIA COLI INFECTION; INFANT; PRESCHOOL CHILD; RENAL REPLACEMENT THERAPY; SHIGA TOXIN PRODUCING ESCHERICHIA COLI;

ANTIBODIES, MONOCLONAL, HUMANIZED; CENTRAL NERVOUS SYSTEM DISEASES; CHILD; CHILD, PRESCHOOL; ESCHERICHIA COLI INFECTIONS; FEMALE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; INFANT; MALE; RENAL DIALYSIS; SHIGA-TOXIGENIC ESCHERICHIA COLI;

EID: 84941369290     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000001000     Document Type: Article

References (32)

1. Karch H, Tarr PI, Bielaszewska M. Enterohaemorrhagic Escherichia coli in human medicine. Int J Med Microbiol. 2005;295:405–418.
2. Gasser C, Gautier E, Steck A, et al. Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia. Schweiz Med Wochenschr. 1955;85:905–909.
3. Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet. 2005;365:1073–1086.
4. Trachtman H, Austin C, Lewinski M, et al. Renal and neurological involvement in typical Shiga toxin-associated HUS. Nat Rev Nephrol. 2012;8:658–669.
5. Pennington H. Escherichia coli O157. Lancet. 2010;376:1428–1435.
6. Scheiring J, Rosales A, Zimmerhackl LB. Clinical practice. Today’s understanding of the haemolytic uraemic syndrome. Eur J Pediatr. 2010;169:7–13.
7. Eriksson KJ, Boyd SG, Tasker RC. Acute neurology and neurophysiology of haemolytic-uraemic syndrome. Arch Dis Child. 2001;84:434–435.
8. Otukesh H, Hoseini R, Golnari P, et al. Short-term and long-term outcome of hemolytic uremic syndrome in Iranian children. J Nephrol. 2008;21:694–703.
9. Rooney JC, Anderson RM, Hopkins IJ. Clinical and pathologic aspects of central nervous system involvement in the haemolytic uraemic syndrome. Proc Aust Assoc Neurol. 1971;8:67–75.
10. Sheth KJ, Swick HM, Haworth N. Neurological involvement in hemolytic-uremic syndrome. Ann Neurol. 1986;19:90–93.
11. Schlieper A, Orrbine E, Wells GA, et al. Neuropsychological sequelae of haemolytic uraemic syndrome. Investigators of the HUS Cognitive Study. Arch Dis Child. 1999;80:214–220.
12. Hahn JS, Havens PL, Higgins JJ, et al. Neurological complications of hemolytic-uremic syndrome. J Child Neurol. 1989;4:108–113.
13. Nathanson S, Kwon T, Elmaleh M, et al. Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2010;5:1218–1228.
14. Orth D, Khan AB, Naim A, et al. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. J Immunol. 2009;182:6394–6400.
15. Rees L. Atypical HUS: time to take stock of current guidelines and outcome measures? Pediatr Nephrol. 2013;28:675–677.
16. Lapeyraque A, Malina M, Fremeaux-Bacchi V, et al. Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med. 2011;364:2561–2563.
17. Bauer A, Loos S, Wehrmann C, et al. Neurological involvement in children with E. coli O104:H4-induced hemolytic uremic syndrome. Pediatr Nephrol. 2014;29:1607–1615.
18. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125166s172lbl.pdf. Accessed December 15, 2014.
19. Gitiaux C, Krug P, Grevent D, et al. Brain magnetic resonance imaging pattern and outcome in children with haemolytic-uraemic syndrome and neurological impairment treated with eculizumab. Dev Med Child Neurol. 2013;55:758–765.
20. Donnerstag F, Ding X, Pape L, et al. Patterns in early diffusion-weighted MRI in children with haemolytic uraemic syndrome and CNS involvement. Eur Radiol. 2012;22:506–513.
21. Kielstein JT, Beutel G, Fleig S, et al. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol Dial Transplant. 2012;27:3807–3815.
22. Theobald I, Kuwertz-Broking E, Schiborr M, et al. Central nervous system involvement in hemolytic uremic syndrome (HUS): a retrospective analysis of cerebral CT and MRI studies. Clin Nephrol. 2001;56:S3–8.
23. Thurman JM, Marians R, Emlen W, et al. Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2009;4:1920–1924.
24. Gallo EG, Gianantonio CA. Extrarenal involvement in diarrhoeaassociated haemolytic-uraemic syndrome. Pediatr Nephrol. 1995;9:117–119.
25. Tichaczek-Goska D. Deficiencies and excessive human complement system activation in disorders of multifarious etiology. Adv Clin Exp Med. 2012;21:105–114.
26. Arnaout R, Al Shorbaghi S, Al Dhekri H, et al. C5 complement deficiency in a Saudi family, molecular characterization of mutation and literature review. J Clin Immunol. 2013;33:871–875.
27. Hillmen P, Muus P, Röth A, et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2013;162:62–73.
28. Lienemann T, Salo E, Rimhanen-Finne R, et al. Shiga toxin-producing Escherichia coli serotype O78:H(-) in family, Finland, 2009. Emerg Infect Dis. 2012;18:577–581.
29. Menne J, Nitschke M, Stingele R, et al. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ. 2012;345:e4565.
30. Bielaszewska M, Mellmann A, Zhang W, et al. Characterisation of the Escherichia coli strain associated with an outbreak of haemolytic uraemic syndrome in Germany, 2011: a microbiological study. Lancet Infect Dis. 2011;11:671–676.
31. Vonberg RP, Hohle M, Aepfelbacher M, et al. Duration of fecal shedding of Shiga toxin-producing Escherichia coli O104:H4 in patients infected during the 2011 outbreak in Germany: a multicenter study. Clin Infect Dis. 2013;56:1132–1140.
32. Kern W. Management of patients with EHEC/HUS. Lessons and perspectives from clinical infectious disease specialists. Article in German. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013;56:87–97.